PIK3CD (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta) encodes the p110δ protein, the catalytic subunit of class IA phosphoinositide 3-kinase (PI3K). While classically considered a leukocyte-restricted isoform, p110δ is increasingly recognized as playing important roles in brain-resident immune cells and in neuroinflammatory processes that contribute to neurodegenerative disease pathogenesis[1].
The p110δ isoform is predominantly expressed in immune cells including T cells, B cells, natural killer cells, mast cells, and macrophages. In the central nervous system, p110δ is primarily expressed in microglia, the brain's resident immune cells. Microglial PI3Kδ signaling regulates inflammatory responses, phagocytosis, and cell survival—processes critical to neurodegeneration[2].
The human PIK3CD gene is located on chromosome 1p36.22 and spans approximately 25 kilobases. It encodes a protein of 1,048 amino acids with a molecular weight of approximately 110 kDa.
The p110δ catalytic subunit contains several conserved domains:
Compared to other class I PI3K isoforms (p110α and p110β), p110δ has unique regulatory properties and substrate specificity. It is activated by specific upstream receptors and has distinct cellular functions.
p110δ is highly expressed in:
In the central nervous system, p110δ is expressed primarily in microglia[2:1]:
This immune-cell-restricted expression pattern makes p110δ an attractive target for modulating neuroinflammation without directly affecting neurons.
PI3Kδ signaling in microglia regulates the transition between surveillance (homeostatic) and activated states:
Pro-inflammatory activation: p110δ contributes to signaling cascades that drive production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Inhibition of p110δ reduces microglial inflammatory responses[2:2].
Phagocytosis: PI3Kδ regulates the cytoskeletal changes required for phagocytosis of cellular debris, amyloid-beta plaques, and pathogens. This function is double-edged—effective phagocytosis is protective, but excessive phagocytosis can contribute to synaptic loss.
Cell survival: p110δ-mediated Akt activation promotes microglial survival. In chronic neuroinflammation, microglial apoptosis can lead to loss of surveillance and repair functions.
Peripheral T cells can infiltrate the brain in neurodegenerative diseases. p110δ is critical for:
In AD and PD, peripheral immune cell infiltration contributes to neuroinflammation. Targeting p110δ could reduce this peripheral immune contribution.
Microglial p110δ plays a dual role in Aβ metabolism[3][4]:
Protective functions: p110δ-mediated signaling is required for effective microglial Aβ phagocytosis. Knockdown of p110δ impairs clearance.
Pathogenic functions: Chronic p110δ activation drives excessive inflammation that damages neurons and may impair the brains's native clearance mechanisms.
This duality makes p110δ targeting complex—complete inhibition might impair beneficial phagocytosis.
PI3Kδ inhibitors have shown promise in preclinical AD models:
However, systemic immune suppression raises concerns about infection risk and cancer surveillance.
In Parkinson's disease, microglial activation contributes to dopaminergic neuron death:
p110δ inhibition represents a strategy to modulate microglial inflammation in PD[5]:
Clinical trials of PI3Kδ inhibitors in PD are anticipated, though delivery methods that bypass systemic immune effects remain a challenge.
The therapeutic window for p110δ inhibition depends on:
Several PI3Kδ inhibitors have been developed:
Key challenges for neuroinflammation indications:
PI3Kδ inhibitors have shown efficacy in:
Understanding PIK3CD genetics informs:
Wang R, et al. Phosphoinositide 3-kinase delta in immune cell signaling and neuroinflammation. Neuropharmacology. 2022. ↩︎
Yue K, et al. Microglial PI3Kδ in neurodegenerative diseases. Trends Neurosci. 2022. ↩︎ ↩︎ ↩︎
Huang Y, et al. Targeting PI3K isoforms for Alzheimer's disease therapy. J Affect Disord. 2021. ↩︎
Zhang L, et al. p110δ deficiency protects against amyloid-β induced neuronal damage. Neurobiol Aging. 2020. ↩︎
Kang W, et al. PI3Kδ inhibition as a therapeutic strategy in Parkinson's disease. Nat Commun. 2023. ↩︎